Exclusive: Xianlian Biotechnology Secures Multi‑million‑Yuan Series A Financing, Closing Two Rounds Within Four Months

According to VCBeat, Guangzhou Xianlian Biotechnology Co., Ltd. (hereinafter referred to as Xianlian Biotech) has announced the completion of its new Series A financing, with investment from Symxcom Investment Co., Ltd. The initial round reaches a multi‑million‑yuan scale.

It is worth noting that, since Xianlian Biotech obtained Dongna Investment angel round financing has only passed less than 4 months at a time when the primary healthcare market is becoming increasingly rational, Fibronectin Bio has continuously secured additional capital injections with growth rates exceeding expectations, fully validating Dongna Investment's project sourcing capabilities and post-investment management prowess as an angel investor.

In March 2026, Dongna Investment completed a multi-million RMB angel-round investment in Xianlian Biotech, at which time the company was in a critical phase of transitioning from technology validation to commercialization.

Just 4 Months Later, in July 2026, Xianlian Biotech secured tens of millions in Series A financing from Symxcom Investment, resulting in a rapid surge in the company's valuation.

Within just one quarter, the investment target received premium valuation recognition in the next round of financing, fully demonstrating Dongna Investment's role as an angel investor. In-depth industry insights and project value discovery capability.

As a core functional protein of the extracellular matrix, fibronectin plays an irreplaceable role in wound repair, tissue regeneration, and beauty‑healthcare sectors. Xianlian Biotech is China's only enterprise that has realized the industrial‑scale production of full‑structure animal‑derived fibronectin — a proposition that has been rapidly validated by the market.

Following the transaction closing, Dongna Investment quickly brought in additional investment and industrial resources for Xianlian Biotech. The two sides conducted in‑depth collaboration across multiple dimensions, including product indication selection, regulatory filing strategies, overseas‑expansion roadmap, clinical demands and product positioning. Notably, Dongna Investment introduced listed‑company partners to jointly explore new indications and global‑rights cooperation, further unlocking the company's future growth potential.

Xianlian Biotech has secured two consecutive financing rounds within merely four months, which is mainly attributed to its technically‑replicable‑resistant moat in the industry. Behind this achievement lies a home‑grown Chinese innovation story built on decades‑long persistent efforts from three generations of researchers.

■ Barrier 1: The World‑Exclusive Capacity for Industrial Mass‑Production of Full‑Structure Fibronectin

Xianlian Biotech is the world's‑only enterprise capable of continuous large‑scale production of full‑structure animal‑derived fibronectin. In contrast to the costly lab‑grade reagents supplied by Sigma (US), Xianlian Biotech boasts an annual production capacity of hundreds of tons of pure fibronectin. It fundamentally addresses long‑standing industrial bottlenecks of unstable global supply chains and exorbitant pricing, and realizes "domestic substitution" for this critical biomaterial.

■ Barrier 2: Proprietary "One‑Feedstock, Multi‑Output" Green Co‑Production Process

The company holds core invention patents related to animal blood-derived fibrin and can simultaneously extract multiple high-value functional proteins from a single source of animal body fluid. This establishes a green, intelligent manufacturing model characterized by "multiple products from one source," which significantly amortizes costs and reduces waste emissions, thereby transforming fibronectin from an exorbitantly priced reagent into an industrially scalable raw material.

■ Barrier 3: Products Validated by Thousands of Clinical Cases

The company's products have accumulated thousands of clinical cases, achieving an efficacy rate of 98.7% in repairing chronic hard‑to‑heal wounds such as diabetic foot ulcers. In January 2026, it completed the master file registration for its fibronectin medical device. Its raw materials have over three‑year safe‑use track records in skincare applications, putting the company ahead of the industry in compliance filing standards.

■ Barrier 4: Nearly 40‑Year Technical Heritage & Moat of 30+ Patents

The technology stems from multi‑generational continuous innovation spanning three generations. The company holds more than 30 independent invention patents (including 3 international PCT patents), and has published over 100 papers in authoritative international journals with a cumulative IF (Impact Factor) exceeding 100. It has built an intellectual‑property moat that is hard for new entrants to overcome in the short term.

The successful completion of two financing rounds for Xianlian Biotech marks the progressive validation of the company's value by the capital market. Rather than blind capital herd‑following, these investments represent rational, tier‑ed judgments from capital of diverse backgrounds based on the enterprise's development stages.

● Seed‑round financing anchors the "technology territory": Investors focused on the scarcity and clinical value of the company's full‑structure fibronectin preparation technology, representing professional recognition of the firm's core technical strengths and underlying technical moat.

● Series‑A financing validates the "commercial closed‑loop": Capital shifted focus to the company's commercial closed‑loop capability and full‑value‑chain growth potential. It marks investors' full recognition of the enterprise's leap from a "raw‑material supplier" to an "end‑product brand".

Currently, the company is advancing on two fronts: accelerating the registration process for serious medical products to solidify its professional foundation, while simultaneously pushing forward brand building in the consumer sector to bridge the final gap in the "technology–raw materials–products–brand" value chain.

Recent Milestones:

● In January 2026, completed the registration of the Drug Master File (DMF) for fibronectin raw materials used in medical devices, further strengthening the competitive moat at the raw material source;

● In August 2026, officially launched its first dermatological-grade professional repair brand — Xiankefu.

Xianke Fuju focuses on the skin repair sector, leveraging the company's long-standing accumulation in industry-academia-research collaboration and its full-structure fibronectin preparation technology to adapt cutting-edge repair research outcomes for daily skincare applications.

Its product repair logic is rooted in solid basic research, driven by self-developed technologies at the raw material end, providing a new R&D paradigm for the field of repair skincare.

Guangdong Dongna Private Fund Management Co., Ltd. was established in 2023 as one of the first professional institutions licensed to operate under China's new regulations on private equity funds. The company is committed to becoming a novel equity investment firm that integrates incubation capabilities, investment management expertise, and M&A integration. Currently, its investment focus centers on two key sectors: biopharmaceuticals and vertical AI applications.

Dongna Investment has always been driven by a passion for technological innovation, a reverence for market dynamics, and a deep commitment to industrial integration. Using capital as its vessel and value as its compass, the firm strives to empower visionary founders, transforming each investment into tangible economic value and profound social impact.

In terms of core‑track layout, the firm's Dongna Medical‑Health Fund focuses on four major sectors: import‑substituting innovative medical devices, regenerative medicine for cell therapy, diagnosis and treatment for chronic and degenerative diseases, and AI‑driven pharmaceutical innovation. It makes targeted investments in tech‑driven innovative projects that fill medical gaps and reshape conventional therapeutic approaches.

Leveraging resources from diverse investors, including government-guided funds and listed companies, the company has established a comprehensive industrial resource network spanning tertiary hospitals, primary healthcare institutions, OTC channels, and overseas markets. This network provides portfolio companies with full-spectrum empowerment services, including clinical demand assessment, market channel expansion, strategic planning, technology incubation acceleration, and financing and M&A matchmaking, thereby helping enterprises shorten R&D cycles and accelerate industrialization.

Xianlian Biotech is another benchmark case of Dongna Investment in the field of regenerative medicine. From precise angel-round positioning to a leap in Series A valuation within four months, Dongna Investment has always believed that only by co-incubating and co-creating with high-quality project teams, working together with one heart, can we achieve steady and long-term success.

Going forward, Dongna Investment will continue to partner with Xianlian Biotech, supporting its evolution from a globally leading supplier of fibronectin raw materials into a full-industry-chain leader in the fields of regenerative medicine and regenerative aesthetics.